癌症治疗的新视野和挑战

M. Tan
{"title":"癌症治疗的新视野和挑战","authors":"M. Tan","doi":"10.19080/ctoij.2021.20.556037","DOIUrl":null,"url":null,"abstract":"Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Horizons and Challenges of Cancer Therapy\",\"authors\":\"M. Tan\",\"doi\":\"10.19080/ctoij.2021.20.556037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.\",\"PeriodicalId\":360247,\"journal\":{\"name\":\"Cancer Therapy & Oncology International Journal\",\"volume\":\"27 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Therapy & Oncology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19080/ctoij.2021.20.556037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Therapy & Oncology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/ctoij.2021.20.556037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

癌症是全球最主要的死亡原因之一,也是高质量生活的巨大障碍[1]。仅在2020年,就有1930万新病例,其中近1000万例死亡[2]。据估计,2020年至2030年间,与癌症相关的医疗费用将达到2329亿美元[3]。因此,开发新的和改进的癌症治疗药物,提高患者的生活质量,降低死亡率是势在必行的。目前,越来越多的前瞻性药物和新疗法正在临床试验中进行测试,其中一些已使入组患者受益。在这里,我们将回顾癌症治疗的前夜和挑战,特别关注免疫治疗和靶向治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
New Horizons and Challenges of Cancer Therapy
Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
相关文献
二甲双胍通过HDAC6和FoxO3a转录调控肌肉生长抑制素诱导肌肉萎缩
IF 8.9 1区 医学Journal of Cachexia, Sarcopenia and MusclePub Date : 2021-11-02 DOI: 10.1002/jcsm.12833
Min Ju Kang, Ji Wook Moon, Jung Ok Lee, Ji Hae Kim, Eun Jeong Jung, Su Jin Kim, Joo Yeon Oh, Sang Woo Wu, Pu Reum Lee, Sun Hwa Park, Hyeon Soo Kim
具有疾病敏感单倍型的非亲属供体脐带血移植后的1型糖尿病
IF 3.2 3区 医学Journal of Diabetes InvestigationPub Date : 2022-11-02 DOI: 10.1111/jdi.13939
Kensuke Matsumoto, Taisuke Matsuyama, Ritsu Sumiyoshi, Matsuo Takuji, Tadashi Yamamoto, Ryosuke Shirasaki, Haruko Tashiro
封面:蛋白质组学分析确定IRSp53和fastin是PRV输出和直接细胞-细胞传播的关键
IF 3.4 4区 生物学ProteomicsPub Date : 2019-12-02 DOI: 10.1002/pmic.201970201
Fei-Long Yu, Huan Miao, Jinjin Xia, Fan Jia, Huadong Wang, Fuqiang Xu, Lin Guo
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
BRAF Inhibitors and Control of Mutant BRAF Effects A Policy Brief about Mandatory Fecal Occult Blood Test CAR T - in Cancer: A “Living Drug” New Era of Cancer Therapy ALK Positive Non-Neural Granular Cell Tumour in Two Paediatric Patients- A Case Report Artificial Intelligence from Research to Clinical Practice
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1